PROTECTIVE EFFECTS OF SPARFLOXACIN IN EXPERIMENTAL PNEUMONIA CAUSED BY CHLAMYDIA-PNEUMONIAE IN LEUKOPENIC MICE

The in vivo antichlamydial activities of sparfloxacin and reference drugs were examined in a experimental model of pneumonia caused by Chlamydia pneumoniae in leukopenic mice; their in vitro activities were also examined. The most potent agents in vitro were sparfloxacin (MICs for C. pneumoniae Kajaani and IOL 207, (0.031 and 0.031 mu g/ml, respectively), clarithromycin (0.031 and 0.031 mu g/ml, respectively), and minocycline (0.031 and 0.031 mu g/ml, respectively); these were followed by tosufloxacin (0.063 and 0.125 mu g/ml, respectively) and ofloxacin (0.5 and 0.5 mu g/ml, respectively). The MBCs of sparfloxacin, tosufloxacin, ofloxacin, clarithromycin, and minocycline for these two strains were 0.063 and 0.063 mu g/ml, 0.125 and 0.25 mu g/ml, 1.0 and 1.0 mu g/ml, 0.125 and 0.125 mu g/ml, and 0.25 and 0.25 mu g/ml, respectively. Fatal pneumonia was induced by intranasal inoculation of cyclophosphamide-treated leukopenic mice with C. pneumoniae IOL 207; infiltration of neutrophils and lymphocytes was observed in the lungs of these mice by histopathological examination. The 50% effective dose of sparfloxacin (oral dose of 0.97 mg/kg of body weight) against the pneumonia was the lowest among the drugs tested; this was followed by those of minocycline (2.22 mg/kg), tosufloxacin (3.47 mg/kg), clarithromycin (4.66 mg/kg), and ofloxacin (16.6 mg/kg). The results indicate that it may be worthwhile to use sparfloxacin against C. pneumoniae infections in humans.